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Introduction: The public-private ADVANCE consortium (Accelerated development of vaccine benefit-risk
collaboration in Europe) aimed to assess if electronic healthcare databases can provide fit-for purpose
data for collaborative, distributed studies and monitoring of vaccine coverage, benefits and risks of vac-
cines.
Objective: To evaluate if European healthcare databases can be used to estimate vaccine coverage, benefit
and/or risk using pertussis-containing vaccines as an example.
Methods: Characterisation was conducted using open-source Java-based (Jerboa) software and R scripts.
We obtained: (i) The general characteristics of the database and data source (meta-data) and (ii) a
detailed description of the database population (size, representatively of age/sex of national population,
rounding of birth dates, delay between birth and database entry), vaccinations (number of vaccine doses,egionale
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country studies on the coverage, benefits and rrecording of doses, pattern of doses by age and coverage) and events of interest (diagnosis codes, inci-
dence rates). A total of nine databases (primary care, regional/national record linkage) provided data
on events (pertussis, pneumonia, death, fever, convulsions, injection site reactions, hypotonic hypo-
responsive episode, persistent crying) and vaccines (acellular pertussis and whole cell pertussis) related
to the pertussis proof of concept studies.
Results: The databases contained data for a total population of 44 million individuals. Seven databases
had recorded doses of vaccines. The pertussis coverage estimates were similar to those reported by the
World Health Organisation (WHO). Incidence rates of events were comparable in magnitude and age-
distribution between databases with the same characteristics. Several conditions (persistent crying and
somnolence) were not captured by the databases for which outcomes were restricted to hospital dis-
charge diagnoses.
Conclusion: The database characterisation programs and workflows allowed for an efficient, transparent
and standardised description and verification of electronic healthcare databases which may participate in
pertussis vaccine coverage, benefit and risk studies. This approach is ready to be used for other vaccines/
events to create readiness for participation in other vaccine related studies.
Crown Copyright  2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Vioxx scandal and the subsequent pharmacovigilance
reforms in the United States of America (USA), resulted in the cre-
ation of a system that can monitor safety on more than 100 million
subjects in the USA, currently the Sentinel system. This led to the
creation of other distributed networks that conduct collaborative
multisite studies throughout the world [1–3]. The creation of these
collaborations and the need for regulators to use real-world evi-
dence has also resulted in enhanced efforts to improve trans-
parency about the quality of data sources, methods, definitions,
common data models, analytics and reporting [4–7].
The need to collaborate and use healthcare data to assess vac-
cine safety was recognised in the 90s in the USA and the Vaccine
Safety Datalink (VSD) was the first multi-site network set up to
use health data [8]. This was then extended by the Post-licensure
Rapid Immunization Safety Monitoring program (PRISM)/FDA Sen-
tinel prior to the 2009 H1N1 influenza pandemic [9]. The VSD con-
ducted extensive data quality checks at its inception, focusing on
validation of completeness of data on vaccinations [10]. Recently,
the FDA assessed the surveillance capabilities of PRISM by charac-
terising the underlying data and concluded that the data on vac-
cine exposures and health outcomes appeared complete enough
to support robust safety monitoring [9].
Large healthcare databases have been used to study the use and
outcomes of therapeutics for several decades [1]. The size of the
populations they cover allows the study of infrequent events and
their representativeness of routine clinical care makes it possible
to study real-world safety, effectiveness and drug utilisation pat-
terns [11,12]. In addition, they are accessible to many researchers
since they can be available at relatively low cost and without long
delays. A recent review of post-authorisation safety studies regis-
tered in the European Post-Authorisation Study register showed
30–50% of studies used healthcare databases to perform post-
authorisation mandatory studies [13]. While the use of these data-
bases offers potential significant advantages, in the past the quality
of routine healthcare data was often questioned [14,15]. Data in
routine healthcare databases are recorded for purposes other than
research and may not be suitable for use as such. The use of real-
world evidence for regulatory decision-making requires assurance
about the quality of the data.
The Accelerated Development of VAcciNe benefit-risk Collabo-
ration in Europe project (ADVANCE) is a public-private consortium
of 47 organisations [16]. The ADVANCE consortium vision was to
deliver best evidence at the right time to support decision-
making on vaccination in Europe. Its mission was to establish araeye, L. van der Aa et al., ADV
isks of pertussis vaccinations, Vprototype of a sustainable and suitable for purpose system that
can rapidly provide the best-available scientific evidence on post-
marketing vaccination benefits and risks for informed decision-
making and effective post-marketing surveillance [2]. The
ADVANCE consortium has designed and tested a system to enable
the generation of evidence on background rates of events of inter-
est, vaccine coverage, benefits and risks following vaccination from
existing distributed healthcare databases [17]. To assess if Euro-
pean healthcare databases that could contribute to ADVANCE are
able to generate evidence suitable for decision making, the
ADVANCE project performed an assessment of their fitness for pur-
pose, based on detailed database characterisation. This paper
describes the parameters, methods and results of the healthcare
database characterisation that were used to evaluate if the data-
bases were fit to participate in the pertussis-related proof of con-
cept (POC) studies performed by ADVANCE and described in
other papers in this supplement [18–24].
2. Methods
2.1. Setting
Database characterisation on population, vaccines and events
was performed in nine European healthcare databases from four
countries: Denmark, Spain, Italy and the United Kingdom (Table 1;
Table 2). Detailed descriptions of these databases can be found in
the Supplementary File.
2.2. Data in the ADVANCE common data model for database
characterisation and assessment
As described in the paper on the ADVANCE system the common
data model comprises three data files: population, events and vac-
cinations [17].
2.2.1. Population
The source population comprised all persons registered in the
database and having at least one day of follow-up during the study
period. Data for all individuals recorded in each database from the
start of follow-up, defined birth or first data availability, whichever
was latest, until the end of follow-up, defined as the date at last
data retrieval, leaving the database (moving out of area/other pro-
vider), or death whichever date was earliest, were used to define
the follow-up for database characterisation. The only eligibility cri-
teria were that the date of birth, start and end of follow-up dates,
and gender needed to be present. The study period varied betweenANCE database characterisation and fit for purpose assessment for multi-
accine, https://doi.org/10.1016/j.vaccine.2020.01.100
Table 1
Characteristics of databases included in the fit-for-purpose assessments.
Country Denmark Spain Italy United Kingdom
Name AUH SSI BIFAP SIDIAP PEDIANET Val Padana Tuscany THIN RCGP
Type of organisation
providing access
Different public data holders Spanish Agency of
Medicines and
Medical Devices
Public research
organisation
Private
organisation;
vaccines from public
health
Local public health
agency
Regional public health
agency
Academic
License holder
(Erasmus MC)
Charity
Origin of data Hospital discharge diagnoses
linked to population and
vaccination registries. National
health care
Family
paediatricians and
general
practitioners
medical records
Family
paediatricians and
general
practitioners
medical records
Family
paediatricians
medical records
linked to Veneto
vaccine register
Hospitalisation
discharge diagnoses
linked to population
and vaccination
registries
Hospitalisation
discharge diagnoses
linked to population
and vaccination
registries
General
practitioners
medical
records
General
practitioners
medical records
Geographic spread Regional National Multiregional 9 out
of 17
Catalunya Region Sample from Veneto
Region
Regional, province Tuscany Region National
sample
National sample
Data governance Approval
Danish Data
protection
Agency
Approval
Danish Data
Protection
Agency
posterior check
Protocol-based
approval
Protocol-based
approval
Generic consent
from parents
collected once
Generic approval Generic approval
(monthly meeting,
posterior check)
Protocol-based
approval
Protocol-based
approval
Age range covered All All All 0–14 years All All All All
Disease diagnosis
coding
ICD-10 Danish version ICD-9, ICPC & text ICD-10 ICD-9 and text ICD-9 ICD-9 READv2 READCTV3 &
READv2
Type of outcomes
covered
Emergency visits, hospitalisation,
death
Primary care,
incomplete
specialist &
hospitalisations
only if GP enters
Primary care,
specialist &
hospitalisations
Primary care,
incomplete
specialist &
hospitalisations
only if FP enters
Only hospitalisations Hospitalisations,
emergency visits, death
Primary care,
specialist &
hospitalisations
Primary care,
incomplete
specialist &
hospitalisations
only if GP enters
Local coding of
vaccines
ATC, local code
&
reimbursement
database
ATC & local
code, before
2013
reimbursement
database
Local code Regional code
mapped to CVX code
Italian marketing
authorisation code
(‘AIC’)
READ codes
and prevention
records
READ codes
POC studies
participation
FP
POC1
FP
POC1POC1.2
FP
POC1
FP
POC1
FP
POC1
FP
POC1.2
FP
POC1.2
FP
POC1
FP
POC1
POC1.2
FP = fingerprint (feasibility assessment), POC1: coverage, benefit, risk and benefit-risk proof of concept study 1, POC1.2: Near real-time monitoring of pertussis vaccine coverage, benefits and risks proof of concept study 1.2
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Table 2
Characteristics of the population (with one year of follow-up) used as input for event incidence calculations for databases participating in the ADVANCE proof of concept studies
(POC-1/POC1.2).
Country Denmark Spain Italy United Kingdom Total
Name AUH SSI BIFAP SIDIAP PEDIANET Val
Padana
Tuscany THIN RCGP RSC
Calendar years
covered
1900–2016 1995–2014 2003–2014 2005–2015 2003–
2015
2001–
2016
2002–2016 1985–2015 1989–2016
Birth date
rounding rule
None None None Day
rounded to
1st of
month
Day
rounded
to 15th of
month
None None Children
rounded to
1st of
month,
adults to
year
Day
rounded to
1st of
month
Total person/years
(% of total)
81,400,848*
(22%)
98,026,412
(27%)
29,997,580
(8%)
51,024,109
(14%)
414,765
(0%)
4,435,896
(1%)
48,423,256
(13%)
28,468,872
(8%)
22,291,050
(6%)
364,482,788
(100%)
Person/years from
1995 onwards
20,865,425 98,026,412 29,997,580 51,024,109 414,765 4,435,896 48,423,256 26,658,434 21,159,284 301,005,161
0–1 years 622,864 2,471,899 711,039 1,66,827 82,864 83,363 802,313 681,813 541,281 5,997,436
2–4 years 934,265 3,583,064 898,961 1,648,703 110,115 116,853 1,160,487 904,224 747,564 10,104,236
5–14 years 3,054,841 11,989,508 2,745,172 5,048,430 221,786 404,588 3,942,729 3,028,660 2,434,910 32,870,624
15–24 years 3,866,239 11,530,630 4,972,367 4,895,042 382,962 4,000,839 2,868,736 2,371,168 34,887,983
25–44 years 4,980,525 272,710,60 9,423,903 16,699,777 1,178,090 13,173,859 7,467,315 6,056,917 58,980,386
45–64 years 4,903,891 25,800,887 6,920,756 12,673,461 1,247,479 13,279,552 7,042,736 5,662,642 77,531,404
65+ years 2,502,800 15,379,365 4,325,382 8,891,869 1,022,561 11,2063,476 4,664,949 3,344,803 149,692,405
4 M. Sturkenboom et al. / Vaccine xxx (xxxx) xxxdatabases, depending on when the database collection started and
ended in 2017. Data access providers created a population file in
the format of the common data model (CDM) (patient ID, date start
follow-up, date end follow-up, birthdate, gender), which was then
analysed to estimate the population size, its gender, age and
follow-up distribution and representativeness in comparison with
the national population statistics.2.2.2. Events
The coverage, benefit and risk POC studies for pertussis contain-
ing vaccine required data for several vaccine risk and effectiveness
outcomes. The outcomes included the following events: convul-
sions/seizures (any type), death, febrile convulsions, fever, gener-
alised convulsions, hypotonic hyporesponsive episode (HHE),
injection site reactions, persistent crying, pertussis, pneumonia,
and somnolence. The outcomes were defined using definitions
from the Brighton Collaboration, learned societies, the World
Health Organization (WHO) or the European Centre for Disease
prevention and Control [19,20]. The case definitions were mapped
to an initial list of the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9), and tenth revision (ICD-10),
Read and the International Classification of Primary Care (ICPC)
codes using the ADVANCE Code mapper tool that maps between
dictionaries using the Unified Medical Language System [25]. Data
access providers (DAPs) for each database were asked to modify
and validate the proposed codes based on local coding habits and
prior experience. Each DAP extracted the final list of codes for
the specific events in their local terminology and transformed the
data into the event file of the common data model containing the
following fields: patient ID, event type, date, original code (ICD-
9/10, Read, ICPC, text) [17]. This event file was linked to the popu-
lation file to calculate event incidence rates and to assess whether
these rates were as expected, as a demonstration of suitability. The
extracted event codes for each database are listed in supplemen-
tary Table S1.2.2.3. Vaccination
The exposure of interest for the initial round of POC studies was
vaccination with whole cell or acellular pertussis (wP or aP, respec-
tively) containing vaccines. The DAPs extracted data for pertussis
vaccination based on local coding and transformed the data into
the vaccine input file which contained the fields: patient ID, vac-Please cite this article as: M. Sturkenboom, T. Braeye, L. van der Aa et al., ADV
country studies on the coverage, benefits and risks of pertussis vaccinations, Vcine type, ATC, brand, date, dose-recorded, dose-derived [17]. The
vaccine type (vactype) was identified as aP or wP, when possible,
and when not, it was unknown type (uP). The vaccine dose was
recorded as 1, 2, 3 or booster dose. When the dose was not
recorded in the data source it was derived by the DAP based on
imputations from the chronological order of the individual’s vacci-
nation dates and the national recommended vaccination schedule.2.2.4. Data management and analyses
The DAPs extracted data from their database using the local
data format and software, which were transformed into the
ADVANCE CDM (CSV format) [17]. We used Jerboa data processing
software, which is JAVA-based, for event code counting and inci-
dence calculations and R scripts for vaccine descriptions and cover-
age estimations [26]. The Jerboa software has been used for
multiple studies and is freely available [27]. The R script for vacci-
nation fingerprinting was created specifically for ADVANCE and is
described in Table S2. The scripts and instructions were sent to
the DAPs, who ran the scripts against their input files and the out-
puts were sent through a secure file transfer protocol (File Zilla or
HighTail) to a remote research environment (RRE) [17].
To assess the population input file we investigated the follow-
ing indicators from the Jerboa output: the size of the population
(number of persons and person-time) by data source, age, calendar
year, exit years and entry years and the time from birth till first
registration, rounding of birthdates and persontime by birth year
using the relevant R-script.
The event characterisation included code counts by type of
event and database and event incidence rates in the population
by calendar year, gender and age. Age was categorised per year
until 17 years old, from 18 to 24 years, and then in 5- year cate-
gories. We subsequently categorised age in 0–1, 2–4, 5–14, 15–
24, 25–64, 65 and older for description, as this coincides with
age of routine vaccination in general and because this categorisa-
tion was compatible with the PRISM database age categories and
therefore age-specific comparisons of incidence rates were possi-
ble [9]. For the population and incidence estimates calculated with
Jerboa, there was one-year run-in period, except for individuals
with an entry date within 6 months of birth, those persons all
started follow-up at birth. Events recorded in the one year run-in
prior to start of follow-up were not considered to be incident
and only first events were considered to be incident. To have aANCE database characterisation and fit for purpose assessment for multi-
accine, https://doi.org/10.1016/j.vaccine.2020.01.100
M. Sturkenboom et al. / Vaccine xxx (xxxx) xxx 5comparable period of calendar time across databases, incidence
rates were limited to calendar years 1995–2016, if these were
available.
Vaccine coverage was estimated to allow comparisons of 1-year
coverage estimates with external coverage estimates as a marker
for completeness. Vaccination coverage was estimated by birth-
year using various methods; here we report the cumulative distri-
bution function-based estimates that correct for left and right cen-
soring [28]. To estimate pertussis coverage, only individuals born
between 1990 and 2015 were selected, and to limit impact of left
censoring, only those with a follow-up start date within 30 days
of birth date were included.
The results of the data characterisation outputs were compared
with external benchmarks and discussed with the DAPs who could
then update the input files and repeat the assessment until they
considered it was appropriate. The DAPs completed a feasibility
assessment sheet to summarise their data and then the DAPs and
study teams for the different pertussis POC studies decided on
the suitability of the database to participate in the POC studies.
All DAPs that had completed this process by November 2016 were
eligible to participate in the first series of POC studies on pertussis
vaccine coverage, benefits, risks and benefit/risk [18–21,23]. The
DAPs that completed the assessment by January 2018 could also
participate in a second POC that focused also on the same pertussis
containing vaccines and benefit and risk outcomes, but tested
prospective near real time monitoring (POC1.2) [24].3. Results
Nine databases participated in the event and vaccine fit-for-
purpose assessment. Five of these databases collected longitudinal
medical record data from multiple health professionals and the
other four were regional or national record linkage systems
(Table 1). Access to the databases was provided by public health
organisations or regulatory agencies (SSI, BIFAP, ARS, ATSVP), pub-
lic research organisations (AUH, RCGP RSC, SIDIAP). PEDIANET is a
private research organisation that agreed to provide access, and for
THIN, access was via a license held by Erasmus Medical Centre (an
academic institute and partner in ADVANCE). Two databases
(ATSVP and ARS) could not participate in the first POC studies as
they did not meet the timelines but they contributed to the
POC1.2 pertussis near real-time monitoring study (Table 1) [24].
3.1. Population characterisation
The period of data availability varied between the databases,
with AUH having data available for the longest period (Table 2).
Table 2 and Fig. 1 show the results of the population characterisa-
tion based on the Jerboa based event fingerprinting output (limit-
ing the population to persons with at least one year of history to be
able to estimate incidence). The total follow-up time for the 34
million individuals with at least one year of data in the nine data-
bases was 364,482,788 person-years. Limiting the person time to
calendar years from 1995 onwards reduced this to 301,005,161
person-years. The largest overall contribution of person-years of
follow-up (27%) was from the SSI database (Fig. 1; Table 2). All
databases were representative in gender and age distributions
with their national statistics, with a slight underrepresentation of
very old persons (>80 year) (data reported as deliverable 5.2 in
ADVANCE project).
3.2. Event characterisation
The incidence rates of some of the events of interest by calendar
year showed peaks in the earlier years of follow-up but were morePlease cite this article as: M. Sturkenboom, T. Braeye, L. van der Aa et al., ADV
country studies on the coverage, benefits and risks of pertussis vaccinations, Vstable in the later years (Fig. 2). Age-specific incidence rates were
comparable between similar types of databases (record linkage,
GP type) in the same country (Table 3, Fig. 2), most rates were
highest in the youngest age categories, pneumonia was high in
the youngest and olders categories, whereas death rates were high-
est in the 65+ category. Temporal patterns were observed for some
databases (Fig. 2). In the ARS database the incidence of all events
increased after 2009 when records of emergency visits became
available. Persistent crying could not be extracted from the AUH,
SSI or SIDIAP databases using ICD-10, due to the absence of codes
specific for this event. Rates of the other events in the general prac-
tice based databases were comparable within countries, except for
fever. The rates for fever showed the largest variation because in
the BIFAP and PEDIANET databases data for fever could also be
extracted using free text, which increased sensitivity, and in the
BIFAP database fever associated with other illnesses, signs or
symptoms was also included. In the RCGP RSC and SIDIAP data-
bases, the incidence rates for most events increased over time
(Fig. 2).3.3. Vaccine characterisation
The total population without limitations in duration in follow-
up that was used for vaccine fingerprinting comprised
44,398,858 persons (Table 4). The percentage of individuals regis-
tered within 6 months of birth was high for recent birth years,
compared with earlier years (Fig. 3). The percentage of persons reg-
istered from birth in older birthyears was lower in the primary care
databases, suggesting censoring and incompleteness of follow-up
from birth.
Data for more than 14 million dose of aP were captured in the
nine databases and dates for almost 7 million doses of wP vaccina-
tions were captured in four databases (RCGP RSC, THIN, SSI and
BIFAP) (Table 4). Data on the recorded vaccine doses were available
in seven of the databases but not for the ATSVP and RCGP RSC data-
bases. Pertussis vaccine coverage estimates based on the cumula-
tive distribution function (CDF) were calculated for specific birth
years and were similar to those reported to WHO by the countries,
except for early birth years in ATSVP (Fig. 4) [29]. The ARS database
did not have vaccination data available for birth cohorts until 2012,
at the moment of the database characterization execution.4. Discussion
This paper describes the characterisation of study populations
from the nine databases participating in the ADVANCE project
located in Denmark, Spain, Italy and the United Kingdom. These
databases included data for more than 44 million individuals and
more than 360 million years of follow-up. Our analyses showed
that the system works, i.e., that the data on the population, vacci-
nations and events from the databases could be transformed
locally and analysed using a simple common data model. The cur-
rent CDM was mapped to concepts locally by the DAP according to
specific supplied rules, which may be adapted for subsequent stud-
ies (adaptive rule system), but for the future we recommed the use
of more organizing models, which will provide more transparency
and centralized options for the mapping to concepts. Standardised
Jerboa and R programs were sent to the DAPs who used them to
generate output that was used to create fit-for-purpose assessment
indicators, such as population distributions, dynamics, incidence
rates of events and vaccination exposure and coverage that were
reviewed and approved by the DAPs. Using this model we were
able to perform a fit-for-purpose assessment of the databases prior
to their participation in specific protocol-based studies on pertus-
sis vaccination as described in this supplement.ANCE database characterisation and fit for purpose assessment for multi-
accine, https://doi.org/10.1016/j.vaccine.2020.01.100
Fig. 1. Follow-up time in person/yearsx106 by calendar year.
Fig. 2. Incidence rates (per 1000 person/years on Y-axis) of first occurrence of the indicated events of interest (per 1000 person/years) (all ages) by calendar year, to assess
any changes in recording of diagnoses over time (A) General practice-based databases; (B) Hospital-based databases.
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M. Sturkenboom et al. / Vaccine xxx (xxxx) xxx 7The key findings of this fit-for-purpose assessment showed,
first, that information on more than 21 million doses of
pertussis-containing vaccinations were available across the nine
databases, providing combined power to study both benefits and
risks of events following pertussis vaccination. Coverage estimates
of the first dose of pertussis-containing vaccinations were compa-
rable to the estimates that the countries report to the WHO, sug-
gesting that, although, in some databases, the data were
incomplete for the earlier years of data collection, they were com-
plete in the later years on a population level.
Second, the periods covered by the databases differed and inci-
dence rates of events in initial years were not always similar to
those for more recent years, probably due to changes in recording
and/or completeness. Third, certain events associated with vacci-
nation reactogenicity (e.g. somnolence, fever and persistent crying)
could be reliably extracted from primary care-based databases, and
to a certain extent from databases with emergency visits (e.g. ARS),
but not from databases capturing only hospital discharge diag-
noses. This demonstrates that databases from different settings
can provide complementary data when included in studies. Fourth,
the incidence rates for the events of interest were similar between
databases of the same type, demonstrating the success of our ter-
minology mapping and harmonisation processes. Also, the data
were similar to public or published benchmark data (Table S1).
For example, the age-specific incidence rates for convulsions and
seizures in the PRISM data in the USA were comparable with the
incidence rates in the included European record linkage and gen-
eral practice databases [9]. In addition, our incidence rates for feb-
rile and generalised seizures were similar to previously published
European data [30]. No publicly available benchmark data werePlease cite this article as: M. Sturkenboom, T. Braeye, L. van der Aa et al., ADV
country studies on the coverage, benefits and risks of pertussis vaccinations, Vavailable for other events, except for pneumonia, death and pertus-
sis rates. An overview of studies on community-acquired pneumo-
nia leading to hospitalisations, reported incidence rates of between
5 and 20 per 1000 person/years for patients aged 65 years and
older, which is consistent with the rates we found in the record
linkage databases [31]. Prior to introduction of pneumococcal
vaccine, the incidence rate of clinical pneumonia in children aged
0–5 years old was reported to be 0.06 episodes per child/year in
Europe [32]. The incidence rates in the primary care databases in
our study were similar but the rates in hospital-based database
were lower, which is to be expected as not all children with
community-acquired pneumonia will be hospitalised. Our esti-
mates for pertussis rates were based on the diagnoses recorded
in the databases, and for Denmark the rates were similar to those
for laboratory-confirmed diagnoses. For other countries, compar-
isons made with national surveillance data showed similarity
[19,22]. Death rates were similar to those from national statistics.
And lastly, the populations of the databases were representative of
their national populations, in age and gender, even if the databases
enrolled only a sample of the population.
Although our results from this database characterisation and
fit-for-purpose assessment suggest the utility of the proposed sys-
tem, we recognise that we used our own indicators. Selection of
additional indicators to assess whether databases are fit-for-
purpose for vaccine-related studies could be performed with other
distributed vaccine-oriented data networks such as Vaccine Safety
Datalink, and PRISM. Europe is challenging as many coding sys-
tems and practices are used in the diverse health care systems.
Databases collect information from disparate provenances, ham-
pering the use of a deep common data model, where all the rawANCE database characterisation and fit for purpose assessment for multi-
accine, https://doi.org/10.1016/j.vaccine.2020.01.100
Table 3
Number of event and incidence rates (95% confidence intervals) per 1000 person-years aggregated across all calendar years.
Denmark Spain Italy United Kingdom
AUH SSI BIFAP SIDIAP PEDIANET Val
Padana
Tuscany THIN RCGP
Pertussis (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
671; 122;
188; 135;
237; 217;
74
3987; 2280;
5506; 744;
1628; 810;
260
467; 158;
415; 48; 145;
62; 25
1406; 730;
2045; 145;
508; 327;
114
65; 103;
146
10; 0; 6;
1; 1; 0; 0
523; 265;
261; 71;
183; 240;
258
321; 182;
269; 75;
178; 155; 55
218; 136;
321; 113;
351; 338; 84
IR0-1 0.2 (0.2,
0.2)
1.6 (1.6, 1.7) 0.7 (0.6, 0.7) 1.2 (1.1, 1.3) 0.8 (0.6,
1.0)
0.1 (0.1,
0.2)
0.7 (0.6,
0.7)
0.4 (0.4, 0.5) 0.4 (0.3, 0.4)
IR2-4 0 (0, 0) 0.6 (0.6, 0.7) 0.2 (0.1, 0.2) 0.4 (0.4, 0.5) 0.9 (0.8,
1.1)
0 (0, 0) 0.2 (0.2,
0.3)
0.2 (0.2, 0.2) 0.2 (0.1, 0.2)
IR 5-14 0 (0, 0) 0.5 (0.4, 0.5) 0.2 (0.1, 0.2) 0.4 (0.4, 0.4) 0.7 (0.6,
0.8)
0 (0, 0) 0.1 (0.1,
0.1)
0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
IR 15-24 0 (0, 0) 0.1 (0.1, 0.1) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0.1)
IR 25-44 0 (0, 0) 0.1 (0.1, 0.1) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.1 (0, 0.1)
IR 45-64 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.1 (0.1, 0.1)
IR 65+ 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Death (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
430, 62,
144, 565
2872,
20,297,
106,090
3884; 592;
1335; 5062;
28,210;
164,038;
808,138
363; 219;
516; 1868;
8918;
31,058;
161,527
523; 236;
557; 1211;
10,002;
46,171;
330,119
1; 2; 4 43; 17;
37; 155;
816;
5139;
44,446
221; 126;
332; 930;
6134;
35,800;
376,965
450; 128;
351; 1124;
5568;
28,563;
181,013
167; 58;
112; 482;
2522;
12,091;
83,162
IR0-1 1.1(1.0,
1.2)
1.6 (1.5, 1.6) 0.5 (0.5, 0.6) 0.4 (0.4, 0.5) 0 (0, 0.1) 0.5 (0.4,
0.7)
0.3 (0.2,
0.3)
0.6 (0.5, 0.7) 0.3 (0.2, 0.3)
IR2-4 0.1(0.1,
0.1)
0.2 (0.2, 0.2) 0.2 (0.2, 0.3) 0.1 (0.1, 0.2) 0 (0, 0.1) 0.1 (0.1,
0.2)
0.1 (0.1,
0.1)
0.1 (0.1, 0.2) 0.1 (0.1, 0.1)
IR 5-14 0.1(0.1,
0.1)
0.1 (0.1, 0.1) 0.2 (0.2, 0.2) 0.1 (0.1, 0.1) 0 (0, 0) 0.1 (0.1,
0.1)
0.1 (0.1,
0.1)
0.1 (0.1, 0.1) 0 (0, 0.1)
IR 15-24 0.3(0.3,
0.4)
0.4 (0.4, 0.5) 0.4 (0.4, 0.4) 0.2 (0.2, 0.3) 0.4 (0.3,
0.5)
0.2 (0.2,
0.2)
0.4 (0.3, 0.4) 0.2 (0.2, 0.2)
IR 25-44 0.8(0.8,
0.8)
1.0 (1.0, 1.0) 0.9 (0.9, 1) 0.6 (0.6, 0.6) 0.7 (0.6,
0.7)
0.5 (0.5,
0.5)
0.7 (0.7, 0.7) 0.4 (0.4, 0.4)
IR 45-64 5.2(5.1,
5.3)
6.4 (6.3, 6.4) 4.5 (4.4, 4.5) 3.6 (3.6, 3.7) 4.1 (4,
4.2)
2.7 (2.7,
2.7)
3.8 (3.8, 3.9) 2 (2.0, 2.1)
IR 65+ 45.3(45.0,
45.5)
52.5 (52.4,
52.7)
37.3 (37.2,
37.5)
37.1 (37,
37.3)
43.5
(43.1,
43.9)
31.3 (31,
31)
36.5 (36.3,
36.7)
24.5 (24.3,
24.7)
Pneumonia (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
7160,
1867,
1360, 939,
4485,
13,015,
36,910
53,261;
17,585;
11,550;
9026;
42,453;
99,749;
286,540
10,528;
17,239;
13,871;
6999;
23,597;
25,537;
36,522
19,543;
37,677;
29,617;
6098;
37,251;
39,140;
56,818
665;
2059;
1587
504;
640;
570;
120;
618;
1684;
8100
7184;
7431;
6177;
1697;
8936;
18,492;
102,845
1060; 973;
909; 616;
2920; 5141;
16,806
1155; 1008;
902; 581;
2956; 4835;
11,779
IR0-1 19.3(18.8,
19.7)
22.0(21.9–
22.2)
15 (14.7,
15.3)
16.9 (16.7,
17.2)
8.1 (7.5,
8.7)
6.1 (5.6,
6.6)
9.0 (8.8,
9.3)
1.4 (1.3, 1.5) 2.0 (1.9, 2.1)
IR2-4 3.7(3.5,
3.8)
5.2(5.1–5.2) 20.4 (20.1,
20.7)
24.5 (24.3,
24.8)
19.5
(18.7,
20.4)
5.6 (5.0.
2, 6)
6.6 (6.4,
6.8)
1.0 (0.9, 1.1) 1.3 (1.2, 1.4)
IR 5-14 0.8(0.7,
0.8)
1.0(1.0–1.02) 5.3 (5.2, 5.4) 6.4 (6.3, 6.5) 7.7 (7.3,
8.1)
1.4 (1.3,
1.6)
1.6 (1.6,
1.7)
0.3 (0.3, 0.3) 0.4 (0.3, 0.4)
IR 15-24 0.6(0.5,
0.6)
0.8(0.8–0.8) 1.4 (1.4, 1.5) 1.3 (1.2, 1.3) 0.3 (0.3,
0.4)
0.4 (0.4,
0.5)
0.2 (0.2, 0.2) 0.2 (0.2, 0.3)
IR 25-44 1.3(1.2,
1.3)
1.6(1.5–1.6) 2.5 (2.5, 2.6) 2.3 (2.2, 2.3) 0.5 (0.5,
0.6)
0.7 (0.7,
0.7)
0.4 (0.4, 0.4) 0.5 (0.4, 0.5)
IR 45-64 3.4(3.4,
3.5)
3.9(3.9–4.0) 3.8 (3.7, 3.8) 3.2 (3.1, 3.2) 1.4 (1.3,
1.4)
1.4 (1.4,
1.4)
0.7 (0.7, 0.7) 0.8 (0.8, 0.8)
IR 65+ 17.1(16.9,
17.3)
20.0(19.9–
20.0)
8.7 (8.6, 8.8) 6.6 (6.6, 6.7) 8.1 (8,
8.3)
8.7 (8.7,
8.8)
3.5 (3.4, 3.5) 3.5 (3.5, 3.6)
Convulsions (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
11,264;
3759;
1440;
1827;
2190;
2735;
2142
42,501;
13,874;
5631; 6059;
12,085;
14,501;
11,239
3209; 1752;
586; 426;
726; 543;
822
6702; 3649;
1509; 557;
1159; 867;
1179
330; 276;
102
625;
350;
155; 27;
23; 62;
72
5138;
3115;
1315; 202;
349; 416;
1107
1638; 1168;
2022; 2219;
4239; 3951;
4118
1044; 809;
1302; 1597;
2903; 2706;
2894
IR0-1 3.5 (3.4,
3.6)
17.4 (17.3,
17.6)
4.5 (4.4, 4.7) 5.8 (5.6, 5.9) 4 (3.6,
4.4)
7.5 (7.0,
8.2)
6.4 (6.3,
6.6)
2.2 (2.1, 2.3) 1.8 (1.7, 1.9)
IR2-4 0.8 (0.8, 4.0 (4.0, 4.1) 2 (1.9, 2.1) 2.2 (2.2, 2.3) 2.5 (2.2, 3.1 (2.7, 2.7 (2.6, 1.2 (1.1, 1.3) 1.0 (1.0, 1.1)
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Table 3 (continued)
Denmark Spain Italy United Kingdom
AUH SSI BIFAP SIDIAP PEDIANET Val
Padana
Tuscany THIN RCGP
0.8) 2.9) 3.4) 2.8)
IR 5-14 0.1 (0.1,
0.1)
0.5 (0.5, 0.5) 0.2 (0.2, 0.2) 0.3 (0.3, 0.3) 0.5 (0.4,
0.6)
0.4 (0.3,
0.5)
0.3 (0.3,
0.4)
0.6 (0.6, 0.7) 0.5 (0.5, 0.5)
IR 15-24 0.1 (0.1,
0.1)
0.5 (0.5, 0.5) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0,
0.1)
0.1 (0, 0.1) 0.7 (0.7, 0.8) 0.6 (0.6, 0.7)
IR 25-44 0.1 (0.1,
0.1)
0.4 (0.4, 0.5) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0 (0, 0) 0 (0, 0) 0.5 (0.5, 0.5) 0.5 (0.4, 0.5)
IR 45-64 0.2 (0.2,
0.2)
0.6 (0.6, 0.6) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0 (0, 0.1) 0 (0, 0) 0.5 (0.5, 0.6) 0.5 (0.4, 0.5)
IR 65+ 0.4 (0.4,
0.4)
0.7 (0.7, 0.7) 0.2 (0.2, 0.2) 0.1 (0.1, 0.1) 0.1 (0.1,
0.1)
0.1 (0.1,
0.1)
0.8 (0.8, 0.9) 0.9 (0.8, 0.9)
Generalised convulsions
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
560; <5 2493; 1; 4;
0; 11; 3; 2
47; 4; 22; 15;
42; 26; 44
55; 4; 1; 1; 0;
0; 0
4; 0; 0 40; 0; 1;
0; 0; 0; 0
84, 4, 0, 0, 0,
0
106; 16; 8;
10; 15; 12; 9
75; 14; 26;
41; 59; 60;
87
IR0-1 0.2 (0.2,
0.2)
1 (1, 1.1) 0.1 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0.5 (0.3,
0.7)
0.1 (0.1,
0.1)
0.1 (0.1, 0.2) 0.1 (0.1, 0.2)
IR2-4 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0.01) 0 (0, 0) 0 (0, 0)
IR 5-14 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 15-24 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 25-44 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 45-64 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 65+ 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Febrile convulsions
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
10,075;
3529;
1116;
1255;
1523;
1460; 964
36,518;
12,308;
1867; 88;
159; 188;
142
2747; 1531;
206; 32; 23;
10; 29
5233; 2971;
373; 35; 43;
11; 18
243; 201;
24
464;
289; 22;
1; 0; 2; 3
3859, 2574,
520, 22, 23,
34, 53
3388; 1755;
223; 11; 23;
19; 19
2960; 1519;
235; 31; 26;
16; 14
IR0-1 3.1 (3.1,
3.2)
14.9 (14.8,
15.1)
3.9 (3.7, 4) 4.5 (4.4, 4.6) 2.9 (2.6,
3.3)
5.6 (5.1,
6.1)
4.8 (4.7, 5) 4.5 (4.4, 4.7) 5.1 (4.9, 5.3)
IR2-4 0.8 (0.7,
0.8)
3.6 (3.5, 3.6) 1.7 (1.6, 1.8) 1.8 (1.8, 1.9) 1.8 (1.6,
2.1)
2.5 (2.2,
2.8)
2.2 (2.2,
2.3)
1.8 (1.7, 1.9) 1.9 (1.8, 2)
IR 5-14 0.1 (0.1,
0.1)
0.2 (0.2, 0.2) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0.1,
0.2)
0.1 (0,
0.1)
0.1 (0.1,
0.1)
0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
IR 15-24 0.1 (0.1,
0.1)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 25-44 0.1 (0.1,
0.1)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 45-64 0.1 (0.1,
0.1)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 65+ 0.2 (0.2,
0.2)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Hypotonic hyporesponsive episode (HHE) (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
394; 88;
482; 1342;
1916;
3069;
3454
1449; 231;
105; 19; 39;
64; 77
661; 375;
669; 216;
258; 277;
752
594; 312;
540; 117;
168; 223;
542
189; 164;
191
25; 3; 3;
3; 9; 4;
38
290, 43 56,
18, 45, 76,
156
510; 390;
595; 281;
578; 852;
2576
242; 210;
225; 91;
187; 234;
607
IR0-1 0.1 (0.1,
0.1)
0.6 (0.6, 0.6) 0.9 (0.9, 1) 0.5 (0.5, 0.6) 2.3 (2,
2.6)
0.3 (0.2,
0.4)
0.4 (0.3,
0.4)
0.7 (0.6, 0.7) 0.4 (0.4, 0.5)
IR2-4 0 (0, 0) 0.1 (0.1, 0.1) 0.4 (0.4, 0.5) 0.2 (0.2, 0.2) 1.5 (1.3,
1.7)
0 (0, 0.1) 0.0 (0.0,
0.0)
0.4 (0.4, 0.4) 0.3 (0.2, 0.3)
IR 5-14 0 (0, 0) 0 (0, 0) 0.2 (0.2, 0.3) 0.1 (0.1, 0.1) 0.9 (0.7,
1)
0 (0, 0) 0.0 (0.0,
0.0)
0.2 (0.2, 0.2) 0.1 (0.1, 0.1)
IR 15-24 0.1 (0.1,
0.1)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0.0) 0.1 (0.1, 0.1) 0 (0, 0)
IR 25-44 0.1 (0.1,
0.1)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.1 (0.1, 0.1) 0 (0, 0)
IR 45-64 0.2 (0.2,
0.2)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.0 (0, 0.0) 0.1 (0.1, 0.1) 0 (0, 0)
IR 65+ 0.6 (0.6,
0.6)
0 (0, 0) 0.2 (0.2, 0.2) 0.1 (0.1, 0.1) 0 (0, 0.1) 0.0 (0.0,
0.0)
0.5 (0.5, 0.5) 0.2 (0.2, 0.2)
Fever (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
10,124;
7641;
2573;
2640;
4320;
5472;
32,524;
11,401;
9265; 5759;
15,253;
21,899;
31,595
144,568;
61,333;
80,732;
52,934;
74,669;
46,983;
117,893;
74,961;
82,523;
24,069;
72,888;
40,726;
19,010;
7859;
6206
136; 48;
105;
122;
393;
647;
1566
18,502;
11,866;
10,103;
4037;
9915;
9265;
60,896;
34,036;
23,417;
6166;
17,461;
15,998;
45,615;
26,309;
19,591;
7639;
21,212;
21,439;
(continued on next page)
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Table 3 (continued)
Denmark Spain Italy United Kingdom
AUH SSI BIFAP SIDIAP PEDIANET Val
Padana
Tuscany THIN RCGP
9184 42,959 35,704 23,459 15,484 16,275
IR0-1 2.4 (2.3,
2.4)
13.3 (13.2,
13.5)
252.3 (251,
253.6)
111.2 (110.6,
111.8)
296.6
(292.4,
300.8)
1.6 (1.4,
1.9)
23.6 (23.2,
24)
87.9 (87.2,
88.6)
84.7 (83.9,
85.4)
IR2-4 0.5 (0.5,
0.6)
3.3 (3.2, 3.3) 126.6 (125.6,
127.6)
57.5 (57.1,
57.9)
157.5
(154.1,
161)
0.4 (0.3,
0.5)
10.7 (10.5,
10.9)
43.9 (43.5,
44.4)
41.2 (40.7,
41.7)
IR 5-14 0.2 (0.2,
0.2)
0.8 (0.8, 0.8) 43.5 (43.2,
43.8)
19.2 (19,
19.3)
65.9
(64.3,
67.6)
0.3 (0.2,
0.3)
2.6 (2.6,
2.7)
8.7 (8.6, 8.9) 9.2 (9.1, 9.3)
IR 15-24 0.2 (0.2,
0.2)
0.5 (0.5, 0.5) 11.5 (11.4,
11.6)
5.1 (5.1, 5.2) 0.3 (0.3,
0.4)
1 (1, 1) 2.1 (2.1, 2.2) 3.3 (3.2, 3.4)
IR 25-44 0.3 (0.3,
0.3)
0.6 (0.6, 0.6) 8.3 (8.2, 8.4) 4.5 (4.5, 4.5) 0.3 (0.3,
0.4)
0.8 (0.7,
0.8)
2.2 (2.2, 2.2) 3.3 (3.3, 3.4)
IR 45-64 0.7 (0.7,
0.7)
0.9 (0.8, 0.9) 7 (7, 7.1) 3.3 (3.3, 3.3) 0.5 (0.5,
0.6)
0.7 (0.7,
0.7)
2.2 (2.1, 2.2) 3.7 (3.6, 3.7)
IR 65+ 1.8 (1.8,
1.9)
2.1 (2, 2.1) 10.3 (10.2,
10.4)
4.1 (4, 4.1) 1.5 (1.5,
1.6)
1.9 (1.9,
2.0)
3.2 (3.1, 3.2) 4.9 (4.9, 5)
Injection site reactions (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
1213; 990;
2360;
6790;
11,949;
13,295;
9230
1606; 883;
1866; 2375;
7991;
10,977; 9669
1938; 1709;
4704;
11,999;
23,025;
20,537;
12,792
3231; 2750;
9456;
14,522;
54,857;
59,408;
80,976
231; 376;
622
3; 1; 15;
12; 18;
22; 40
426, 124,
349, 243,
788,1191,
2926
2086; 1113;
3777; 7120;
19,597;
18,361;
13,158
808; 468;
1698; 2846;
8429; 8540;
5803
IR0-1 0.4 (0.4,
0.4)
0.7 (0.6, 0.7) 2.7 (2.6, 2.9) 2.8 (2.7, 2.9) 2.8 (2.4,
3.2)
0 (0, 0.1) 0.5 (0.5,
0.6)
2.8 (2.7, 2.9) 1.4 (1.3, 1.5)
IR2-4 0.2 (0.2,
0.2)
0.2 (0.2, 0.3) 1.9 (1.8, 2) 1.7 (1.6, 1.7) 3.4 (3.1,
3.8)
0 (0, 0) 0.1 (0.1,
0.1)
1.2 (1.1, 1.2) 0.6 (0.5, 0.6)
IR 5-14 0.2 (0.1,
0.2)
0.2 (0.1, 0.2) 1.7 (1.7, 1.8) 1.9 (1.8, 1.9) 2.8 (2.6,
3.1)
0 (0, 0.1) 0.1 (0.1,
0.1)
1.2 (1.1, 1.2) 0.7 (0.6, 0.7)
IR 15-24 0.4 (0.3,
0.4)
0.2 (0.2, 0.2) 2.4 (2.4, 2.5) 3 (2.9, 3) 0 (0, 0.1) 0.1 (0.1,
0.1)
2.4 (2.3, 2.4) 1.2 (1.1, 1.2)
IR 25-44 0.6 (0.6,
0.6)
0.3 (0.3, 0.3) 2.5 (2.4, 2.5) 3.3 (3.3, 3.4) 0 (0, 0) 0.1 (0.1,
0.1)
2.5 (2.4, 2.5) 1.3 (1.3, 1.3)
IR 45-64 1 (1, 1) 0.4 (0.4, 0.4) 3 (3, 3) 4.8 (4.7, 4.8) 0 (0, 0) 0.1 (0.1,
0.1)
2.5 (2.5, 2.5) 1.4 (1.4, 1.5)
IR 65+ 1.7 (1.6,
1.7)
0.6 (0.6, 0.6) 3 (2.9, 3) 9.4 (9.3, 9.4) 0 (0, 0.1) 0.2 (0.2,
0.2)
2.7 (2.7, 2.8) 1.7 (1.7, 1.8)
Somnolence (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
22; 23; 89;
551; 1497;
2145;
2839
31; 33; 105;
560; 2080;
2552; 1559
82; 92; 93;
660; 1481;
1428; 2989
79; 69; 117;
256; 1033;
1539; 2606
31; 19; 23 0; 0; 0;
1; 4; 4; 1
130; 102;
171; 79;
199; 412;
2853
449; 214;
184; 280;
1107; 1771;
5316
268; 102;
115; 244;
719; 896;
2819
IR0-1 0 (0, 0) 0 (0, 0) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.4 (0.3,
0.5)
0 (0, 0) 0.2 (0.1,
0.2)
0.6 (0.5, 0.7) 0.5 (0.4, 0.5)
IR2-4 0 (0, 0) 0 (0, 0) 0.1 (0.1, 0.1) 0 (0, 0.1) 0.2 (0.1,
0.3)
0 (0, 0) 0.1 (0.1,
0.1)
0.2 (0.2, 0.3) 0.1 (0.1, 0.2)
IR 5-14 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.1 (0.1,
0.2)
0 (0, 0) 0 (0, 0.1) 0.1 (0, 0.1) 0 (0, 0.1)
IR 15-24 0 (0, 0) 0 (0, 0.1) 0.1 (0.1, 0.1) 0.1 (0, 0.1) 0 (0, 0) 0 (0, 0) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
IR 25-44 0.1 (0.1,
0.1)
0.1 (0.1, 0.1) 0.2 (0.1, 0.2) 0.1 (0.1, 0.1) 0 (0, 0) 0 (0, 0) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
IR 45-64 0.2 (0.1,
0.2)
0.1 (0.1, 0.1) 0.2 (0.2, 0.2) 0.1 (0.1, 0.1) 0 (0, 0) 0 (0, 0) 0.2 (0.2, 0.2) 0.1 (0.1, 0.2)
IR 65+ 0.5 (0.5,
0.5)
0.1 (0.1, 0.1) 0.7 (0.7, 0.7) 0.3 (0.3, 0.3) 0 (0, 0) 0.2 (0.2,
0.2)
1.1 (1, 1.1) 0.8 (0.8, 0.9)
Persistent crying (codes)
Number of events by age group
(0–1; 2–4; 5–14, 15–24, 45–
64 65+)
17,852;
1004; 199;
893; 2197;
1685; 1276
1985;
203; 15
2; 0; 0;
0; 0; 0; 0
2098, 143,
43, 16, 20,
21, 22
3366; 272;
58; 74; 199;
144; 76
4299; 262;
55; 44; 103;
83; 40
IR0-1 25.9 (25.5,
26.3)
24.6
(23.6,
25.7)
0 (0, 0.1) 2.6 (2.5,
2.7)
4.5 (4.4, 4.7) 7.5 (7.2, 7.7)
IR2-4 1.2 (1.1, 1.2) 1.9 (1.7,
2.2)
0 (0, 0) 0.1 (0.1,
0.1)
0.3 (0.2, 0.3) 0.3 (0.3, 0.4)
IR 5-14 0.1 (0.1, 0.1) 0.1 (0,
0.1)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 15-24 0.2 (0.2, 0.2) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 25-44 0.2 (0.2, 0.2) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 45-64 0.2 (0.2, 0.3) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
IR 65+ 0.3 (0.3, 0.3) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
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Table 4
Pertussis vaccine coverage estimated during database fingerprint (all ages).
Denmark Spain Italy United Kingdom
AUH SSI BIFAP SIDIAP PEDIANET Val Padana Tuscany THIN RCGP
Total persons (all ages) no selection
in input file
2,563,188 7,512,032 7,550,262 7,096,695 9708 454,188 4,837,755 11,696,261 2,678,749
Recommended acellular pertussis
vaccine schedule
3,5,12 months, 5 years 2,4, 11 months, 6 years 3,5,11 months, 6 years, 12-18 years,
pregnancy (Tdap)
2,3,4 months, 3 years,15-
45 pregnancy
Exposure
Number of aP doses recorded
(all ages)
751,629 4,089,505 1,750,171 2,846,877 36,124 90,713 403,793 3,295,699 990,135
Number of wP doses of (all ages) 0 22,565 33,588 0 0 0 0 5,986,936 909,606
aP-containing vaccine
combinations (all population)
Not
specified
1-valent:
573
3-valent:
26,344
4-valent:
1,701,864
5-valent:
2,179,619
6-valent:
116,913
3-valent:
368,345
4-valent:
643
5-valent:
828,067
6-valent:
548,166
1-valent:
28,383
2-valent:
587,032
5-valent:
705,940
6-valent:
1,525,522
Not
supplied
3-valent:
10,023
4-valent:
12,404
5-valent:
500
6-valent:
67,786
Not
submitted
Not
submitted
1-valent:
140,911
3-valent:
594
4-valent:
224,245
5-valent:
624,385
Dose recorded or derived Doses
recorded
Doses
recorded
Doses
recorded
Doses
recorded
Doses
recorded
All doses
derived
Doses
recorded
Dose
recorded
All doses
derived
Coverage estimation selected population
Number of persons eligible for
coverage analysis
188,553 1,219,732 293,170 467,960 9,708 18,759 335,062 468,897 46,240
Percentage coverage for D1 aP (CDF) age 12 months by selected birth-year
2006 86 90 92 98 94 71 97 95
2007 90 91 93 97 94 92 97 93
2008 92 92 95 96 98 97 94
2009 92 93 95 96 98 97 94
2010 95 94 90 97 97 97 94
2011 96 94 95 96 98 94
2012 95 94 96 96 98 95
Percentage coverage for D2 aP (CDF) age 12 months
2006 89 88 94 97 93 59 96 94
2007 91 89 94 96 94 87 96 92
2008 92 91 94 95 94 96 93
2009 92 91 94 95 93 96 94
2010 93 92 94 95 94 97 92
2011 94 92 94 95 97 93
2012 94 92 95 95 97 94
D1: dose 1; D2: dose 2, CDF: cumulative distribution function; aP: acellular pertussis vaccine; wP: whole cell pertussis vaccine.
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Although the use of a deep common data model, such as that used
in Sentinel/PRISM, VSD or the OMOP common data models would
enable a broader standardised assessment of quality, its cost makes
it currently not feasible in Europe, due to the absence of sustain-
able public funding for distributed healthcare data networks
[33,34]. This might change in the future with the European Health
Data & Evidence Network (EHDEN) project funded by the Innova-
tive Medicines Initiative, which aims to convert European data
for 100 million individuals into the OMOP common data model
[35]. The initial quality assessment in VSD involved checking the
data against the individual paper records, which was not feasible
in ADVANCE given the resources provided. We, therefore, com-
pared the data between the databases and with external bench-
marks, similar to the approach that was taken in PRISM [9]. In
addition to the events relevant for pertussis studies, auto-
immune disorders of interest and vaccine preventable diseases
were characterised to create further preparedness, these will be
described separately. We currently cannot provide traditional esti-
mates of validity (e.g. sensitivity, positive predictive value) because
we benchmarked our data on a population level. Chart validation
studies on the investigated events had been done in other contexts
in some of the databases (Table S1), showing that in Denmark pos-
itive predictive values were high for ICD10 pertussis code A37Please cite this article as: M. Sturkenboom, T. Braeye, L. van der Aa et al., ADV
country studies on the coverage, benefits and risks of pertussis vaccinations, Vagainst laboratory confirmed cases as well as in Spain for ICD9
(037) and ICPC (R71.1) codes. The PPV for ICD-10 code febrile con-
vulsions (R560) was more than 92% in Denmark in prior hospital-
ization validation studies. Pneumonia hospitalization code ICD10
J12-J18 had PPV of more than 92% in prior validation studies of
hospitalizations in Denmark, and were above 70% in the BIFAP
for ICPC and ICD-9 codes (see Table S1). Medical chart validation
studies may be done in each of the participating data sources,
but this requires considerable resources and ethical approval, and
there was no budget available for this task within the IMI-
ADVANCE funding. Future vaccine effect studies should assure
funding to assess the validity of the event codes on an individual
case level. Additional limitations are the lack of information on
demographic variables other than age and gender to assess repre-
sentativeness of the populations, ethnicity and social economic
status is not generally recorded due its sensitivity. Moreover, we
only assessed the population, vaccine and event data from four
countries of relatively high income countries in Europe. With the
increasing computerization of health care and vaccination reg-
istries we recommed that the follow-up of ADVANCE: the VAccine
monitoring Collaboration for EUrope (VAC4EU) includes additional
countries (preferable eastern) to become more representative of
Europe and cover brands/vaccines provided in those countries as
well.ANCE database characterisation and fit for purpose assessment for multi-
accine, https://doi.org/10.1016/j.vaccine.2020.01.100
Fig. 3. Percentage of children registered within six months after birth by year of birth to verify completeness of follow-up per birth cohort.
Fig. 4. Percentage of pertussis vaccine coverage estimate for dose 1 of acellular pertussis vaccine by calendar year, compared with national estimates for DTaP vaccine
reported to the World Health Organisation.
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tion workflowmodel, based on the ADVANCE common data model,
which enables transparent fit-for-purpose assessment of databases
for specific studies, which was tested in the pertussis vaccination
POC studies described in this supplement [18–24]. The database
characterisation provided a detailed description of the structure
of the population covered by the health care databases, the coding
and incidence rates of events, as well as exposure to vaccines andPlease cite this article as: M. Sturkenboom, T. Braeye, L. van der Aa et al., ADV
country studies on the coverage, benefits and risks of pertussis vaccinations, Vvaccination coverage. Our system enabled comparisons between
database and comparisons with external benchmarks, providing
indicators of completeness of data on a population level. We
showed that the older data in databases may be less reliable than
more recent data and that both age and calendar years patterns
need to be inspected prior to deciding which period is fit-for-
purpose. The ADVANCE project, which has evolved into the Vaccine
monitoring collaboration for Europe (VAC4EU) will aim to makeANCE database characterisation and fit for purpose assessment for multi-
accine, https://doi.org/10.1016/j.vaccine.2020.01.100
M. Sturkenboom et al. / Vaccine xxx (xxxx) xxx 13the data for event rates and coverage estimates available in an
interactive tool which would enable rapid and transparent inspec-
tion of the feasibility of databases to participate in specific studies
[36]. The workflow that was created can easily be extended to
other vaccines and events, to increase readiness and speed in con-
ducting protocol-based vaccine coverage, benefit and risk studies.
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